Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer - An update

Leukemia and Lymphoma

Volumn 46, Issue 5, 2005, Pages 651-663

  Barnard, Dorothy R ^a   Woods, W G ^b  

^a IWK HEALTH CENTRE   (Canada)

^b EMORY UNIVERSITY   (United States)

Author keywords

Pediatric; Treatment related acute myeloid leukemia; Treatment related myelodysplastic syndrome

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ALKYLATING AGENT; AMIFOSTINE; ANTHRACYCLINE; ANTISENSE OLIGONUCLEOTIDE; CD20 ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DIPHTHERIA TOXIN; DNA; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GLUTATHIONE TRANSFERASE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; IFOSFAMIDE; METHOTREXATE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; QUININE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RETINOBLASTOMA PROTEIN; SEMAXANIB; VINCRISTINE; YTTRIUM;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CHILD; CHILDHOOD CANCER; CHILDHOOD MORTALITY; CLINICAL FEATURE; CLINICAL TRIAL; CYTOGENETICS; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; DRUG EFFICACY; HUMAN; INCIDENCE; MORPHOLOGY; MYELODYSPLASTIC SYNDROME; PATHOLOGY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; RISK FACTOR; SECOND CANCER; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 20144363122     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500051042     Document Type: Review

References (116)

1. Neglia JP, Friedman DI, Yasui Y et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001;93:618-629.
2. Kantarjian HM, Keating MJ, Walters RS et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic and prognostic features. J Clin Oncol 1986;4:1748-1757.
3. Pedersen-Bjergaard J, Andersen MK, Christiansen DH et al. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002;99:1909-1912.
4. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochem Biophys Acta 1998;1400:233-255.
5. Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000;95:3273-3279.
6. Leone G, Voso MT, Sica S et al. Therapy-related leukemias: susceptibility, prevention and treatment. Leuk Lymphoma 2001;41:255-276.
7. Felix CA. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 2001;36:525-535.
8. Latagliata R, Petti MC, Fenu S et al. Therapy-related myelodysplastic syndrome - acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002;99:822-824.
9. Meadows AT, Baum E, Fossati-Bellani et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol 1985;3:532-538.
10. Bhatia S, Ramsey NKC, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996;87:3633-3639.
11. Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer 2002;2:124-132.
12. Pui C-H, Ribeiro RC, Hancock ML et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoid leukemia. N Eng Med J 1991;325:1682-1687.
13. Neglia JP, Meadows AT, Robison LL et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Eng J Med 1991;325:1330-1336.
14. Kreissman SG, Gelber RD, Cohen HJ et al. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer 1992;70:2208-2213.
15. Dalton VMK, Gelber RD, Li F et al. Second malignancies in patients treated for childhood acute lymphoblastic leukemia. J Clin Oncol 1998;16:2848-2953.
16. Loning L, Zimmermann M, Reiter A et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000;95:2770-2775.
17. Bhatia S, Sather HN, Pabustan OB et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 2002;99:4257-4264.
18. Wolden SL, Lamborn KR, Cleary SF et al. Second cancers following pediatric Hodgkin's disease. J Clin Oncol 1998;16:536-544.
19. Milligan DW, de Elvira CR, Kolb H-J et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. Br J Haematol 1999;106:1020-1026.
20. Andre M, Henry-Amar M, Blaise D et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998;92:1933-1940.
21. Nichols KE, Levitz S, Shannon KE et al. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol 1999;17:1259.
22. Mott MG, Boyse J, Hewitt M et al. Do mutations at the glycophorin A locus in patients treated for Hodgkin's disease predict secondary leukaemia? Lancet 1994;343:828-829.
23. Leung W, Sandlund JT, Hudson MM et al. Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer 2001;92:1959-1966.
24. Krishnan A, Bhatia S, Slovak ML et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000;95:1588-1593.
25. Metayer C, Curtis RE, Vose J et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003;101:2015-2023.
26. Lillington DM, Micallef INM, Carpenter E et al. Genetic susceptibility to Hodgkin's disease and secondary neoplasias: FISH analysis reveals patients at high risk of developing secondary neoplasia. Ann Oncol 2002;13(Suppl. 1):40-43.
27. Micallef INM, Lillington DM, Apostolidis J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000;18:947-955.
28. Pratt CB, Meyer WH, Luo X et al. Second malignant neoplasms occurring in survivors of osteosarcoma. Cancer 1997;80:960-965.
29. Bhatia S, Krailo M, Schwartz et al. Therapy-related myelodysplasia [t-MDS/t-AML] following treatment of children with osteosarcoma. Am Soc Clin Oncol 2001;20:369a (abstract 1473).
30. Aung L, Gorlick RG, Shi W et al. Second malignant neoplasms in long-term survivors of osteosarcoma. Memorial Sloan-Kettering Cancer Center experience. Cancer 2002;95:1728-1734.
31. Miser J, Krailo M, Smith M et al. Secondary leukemia (SL) or myelodysplastic syndrome (MDS) following therapy for Ewing's sarcoma (ES). Proc Am Soc Clin Oncol 1997;16:1863 (abstract).
32. Rodriguez-Galindo C, Poquette CA, Marina NM et al. Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors. J Pediatr Hematol/Oncol 2000;22:321-329.
33. Pui C-H, Hancock ML, Raimondi SC et al. Myeloid neoplasia in children treated for solid tumors. Lancet 1990;336:417-421.
34. Breslow NE, Takashima JR, Whitton JA et al. Second malignant neoplasms following treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1995;13:1851-1859.
35. Shearer P, Kapoor G, Beckwith JB et al. Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors: a report from the National Wilms Tumor Study Group. J Pediatr Hematol/Oncol 2001;23:109-111.
36. Miwa H, Beran M, Sanders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992;6:405-409.
37. Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy related acute myeloid leukemia and myelodysplastic syndrome. Blood 1985;65:1364-1372.
38. Kouides PA, Bennett JM. Morphology and classification of the myelodysplastic syndromes and their pathologic variants. Semin Hematol 1996;33:95-110.
39. Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-625.
40. Bennett JM, Catovsky D, Daniel MT et al. Criteria for the diagnosis of acute leukemia of megakaryocytic lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:460-462.
41. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
42. Barnard DR, Lange BJ, Alonzo TA et al. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood 2002;100:427-434.
43. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
44. Rege KP, Janes SL, Saso R et al. Secondary leukaemia characterised by monosomy 7 occurring post-autologous stem cell transplantation for AML. Bone Marrow Transplant 1998;21:853-855.
45. Kebelmann-Betzing C. Secondary acute myeloid leukemia after treatment of acute monoblastic leukemia. N Eng J Med 2000;343:1897-1898.
46. Kondoh K, Nakata Y, Furuta T et al. A pediatric case of secondary leukemia associated with t(16;21)(q24;q22) exhibiting the chimeric AML1-MTG16 gene. Leuk Lymphoma 2002;43:415-420.
47. Amigo ML, del Canizo MC, Rois A et al. Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS. Bone Marrow Transplant 1999;23:997-1002.
48. Laurenti L, d'Onofrio G, Sica S et al. Secondary myelodysplastic syndromes following peripheral blood stem cell transplantation: morphological, cytogenetic and clonality evaluation and the limitation of FAB criteria. Bone Marrow Transplant 2000;26:241-242.
49. Chu JY, Batanian JR, Gale GB et al. Spontaneous resolution of myelodysplastic cytogenetic abnormality developed during the treatment of leukemia. J Pediatr Hematol/Oncol 1998;20:88-90.
50. Seiter K, Feldman EJ, Sreekantaiah C et al. Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy. Leukemia 2001;15:963-970.
51. Andersen MK, Pedersen-Bjergaard J. Therapy-related MDS and AML in acute promyelocytic leukemia. Blood 2002;100:1928-1929.
52. Rowley JD. Rearrangements involving chromosome band 11q23 in acute leukemia. Semin Cancer Biol 1993;4:377-385.
53. Rowley JD, Reshmi S, Sobulo O et al. All patients with the t[11;16] [q23;p13.3] that involves MLL and CBP have treatment-related hematologic disorders. Blood 1997;90:535-541.
54. Atlas M, Head D, Behm F et al. Cloning and sequence analysis of four t[9;11] therapy-related leukemia breakpoints. Leukemia 1998;12:1895-1902.
55. Langer T, Metzler M, Reinhardt D et al. Analysis of t[9;11] chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides. Genes Chromosomes Cancer 2003;36:393-401.
56. Quesnel B, Kantarjian H, Pedersen-Bjergaard J et al. Therapy-related acute myeloid leukemia with t(8;21), inv 16 and t(8;16). A report on 25 cases and review of the literature. J Clin Oncol 1993;11:2370-2379.
57. Pedersen-Bjergaard J, Brondum-Nielsen K, Karle H et al. Chemotherapy-related and late occurring Philadelphia chromosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase II inhibitors? Leukemia 1997;11:1571-1574.
58. Forestier E, Heim S, Blennow E et al. Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001. Br J Haematol 2003;121:566-577.
59. Harada H, Harada Y, Tanaka H et al. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 2003;101:673-680.
60. Mauritzson N, Albin M, Rylander L et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002;16:2366-2378.
61. Nabhan C, Peterson LA, Kent SA et al. Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin lymphoma. Leuk Lymphoma 2002;43:2145-2149.
62. Schoch C, Schnittger S, Kern W et al. Acute myeloid leukemia with recurring chromosomal abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia. Haematologica 2003;88:351-352.
63. Preisler HD. Evolution of secondary hematologic disorders: pre-MDS→ MDS→ sAML. Cancer Treat Res 2001;108: 185-230.
64. Davies SM. Therapy-related leukemia associated with alkylating agents. Med Pediatr Oncol 2001;36:536-540.
65. Le Deley M-C, Leblanc T, Shamsaldin A et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 2003;21:1074-1081.
66. Smith MA, Rubinstein L, Anderson JR et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999;17:569-577.
67. Karp JE, Smith MA. Modifying risks of secondary leukemias: is drug scheduling important. J Natl Cancer Inst 1996;88:1787-1789.
68. Haupt R, Fears TR, Heise A et al. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German population. Int J Cancer 1997;71:9-13.
69. Deininger MWN, Bose S, Gora-Tybor J et al. Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation. Cancer Res 1998;58:421-425.
70. 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol/Oncol 2003; 25:543-547.
71. Smith SM, Le Beau MM, Huo D et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102:43-52.
72. Fassas AB, Tricot G. Myelodysplastic syndromes complicating hematopoietic stem cell transplantation. Cancer Treat Res 2001;108:169-184.
73. Forrest DL, Nevill TJ, Naiman SC et al. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis. Bone Marrow Transplant 2003;32:915-923.
74. Lambertenghi-Deliliers G, Annaloro C, Pozzoli E et al. Cytogenetic and myelodysplastic alteration after autologous hematopoietic stem cell transplantation. Leukemia Res 1999;23:291-297.
75. Sevilla J, Rodriguez A, Hernandez-Maraver D et al. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation. Ann Hematol 2002;81:11-15.
76. Relling MV, Boyett JM, Blanco JG et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003;101:3862-3867.
77. Clark JJ, Smith FO, Arceci RJ. Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies. Curr Opin Hematol 2003;10:31-39.
78. Marcaigh AS, Shannon KM. Role of NF1 gene in leukemogenesis and myeloid growth control. J Pediatr Hematol/Oncol 1997;19:551-554.
79. Perentesis JP. Genetic predisposition and treatment-related leukemia. Med Pediatr Oncol 2001;36:541-548.
80. Pagana L, Pulsoni A, Tosti ME et al. Clinical and biological features of acute myeloid leukemia occurring as second malignancy: GIMEMA archive of adult acute leukemia. Br J Haematol 2001;112:109-117.
81. Chen H, Sandler DP, Taylor JA et al. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 1996;347:295-296.
82. Woo MH, Shuster JJ, Chen C et al. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia 2000;14:232-237.
83. Allan JM, Wild CP, Rollison S et al. Polymorphism in glutathione S-transferase P1 associated with susceptibility to chemotherapy-induced leukemia. PNAS 2001;98:11592-11597.
84. Larson RA, Wang Y, Banerjee et al. Prevalence of the inactivating 609C→T polymorphism in the NAD[P]H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999;94:803-807.
85. Relling MV, Yanishevski Y, Nemec J et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998;12:346-352.
86. Seedhouse C, Bainton R, Lewis M et al. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood 2002;100:3761-3766.
87. Stone RM. Treatment of acute myeloid leukemia: state-of-the-art and future directions. Semin Hematol 2002;39:4-10.
88. Head DR. Revised classification of acute myeloid leukemia. Leukemia 1996;10:1826-1831.
89. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-1327.
90. Meltzer PS. MDM2 and p53: a question of balance. J Natl Cancer Inst 1994;84:1265-1266.
91. Felix CA, Hosler MR, Provisor D et al. The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood 1996;87:4376-4381.
92. Ben-Yehuda D, Krichevsky S, Caspi et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996;88:4296-4303.
93. Gustafsson B, Christenson B, Gustafsson B et al. Cellular expression of MDM2 and p53 in childhood leukemias with poor prognosis. Med Pediatr Oncol 2000;34:117-124.
94. Nagai M, Fujita M, Ikeda T et al. Alterations of p53 and Rb genes in a novel human GM-CSF-dependent myeloid cell line (OHN-GM) established from therapy-related leukaemia. Br J Haematol 1997;98:392-398.
95. Qian Z, Fernald AA, Godley LA et al. Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. PNAS 2002;99:14925-14930.
96. Boyse J, Hewitt M, Mott MG. Glycophorin A mutations and risk of secondary leukaemia in patients treated for childhood acute lymphoblastic leukaemia. Br J Haematol 1996;93:117-124.
97. Sandler ES, Friedman DJ, Mustafa MM et al. Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia. Cancer 1997;79:1049-1054.
98. Visani G, Pagano L, Pulsoni A et al. Chemotherapy of secondary leukemias. Leuk Lymphoma 2000;37:543-549.
99. Beaumont M, Sanz M, Carli PM et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003;21:2123-2137.
100. Pollicardo N, O'Brien S, Estey EH et al. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution. Leukemia 1996;10:27-31.
101. Rege K, Swansbury GJ, Atra AA et al. Disease features in acute myeloid leukemia with t[1;21][q22;q22]. Influence of age, secondary karyotype abnormalities, CD19 status and extramedullary leukemia on survival. Leuk Lymphoma 2000;40:67-77.
102. Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic. Genes Chromosomes Cancer 2002;33:331-345.
103. Leahey AM, Friedman DL, Bunin NJ. Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. Bone Marrow Transplant 1999;23:21-25.
104. Hale GA, Heslop HE, Bowman LC et al. Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant 1999;24:735-739.
105. Estey EH. Prognosis and therapy of secondary myelodysplastic syndromes. Haematologica 1998;83:543-549.
106. Wattel E. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P-glycoprotein: results of a randomized study. Br J Haematol 1998;102:1015-1024.
107. Hermida G, Manjon R, Rodriguez-Salazar I, Richard C. Treatment of a secondary myelodysplastic syndrome after allogenic bone marrow transplantation using Mylotarg. Haematology 2002;87:[04]ECR14.
108. Auletta JJ, Shurin S. Improved hematopoiesis using amifostine in secondary myelodysplasia. J Pediatr Hematol/Oncol 1999;21:531-534.
109. List AF, Heaton R, Glinsmann-Gibson B et al. Amifostine stimulates formation of multipotent progenitors and generates macroscopic colonies in normal and myelodysplastic bone marrow. Proc Am Soc Clin Oncol 1996;15:449.
110. Steinmetz HT, Schulz A, Staib P et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside and filgrastim (Ida-FLAG) for treatment of refractory, relapsed and secondary AML. Ann Hematol 1999;78:418-425.
111. He X-Y, Elson P, Pohlman B et al. Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial. BMC Cancer 2002;2:12-18.
112. Kindler T, Breitenbuecher F, Marx A et al. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. Blood 2003;101:2960-2962.
113. Tsutsumi C, Ueda M, Miyazaki Y et al. DNA microarray analysis of dysplastic morphology associated with acute myeloid leukemia. Exp Hematol 2004;32:828-835.
114. Perentesis JP, Sievers EL. Targeted therapies for high-risk acute myeloid leukemia. Hematol/Oncol Clin North Am 2001;15:677-701.
115. Fiedler W, Mesters R, Tinnefeld H et al. A phase II clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003;102:2763-2767.
116. Mantadakis E, Kalmanti M. New antileukemic agents. Pediatr Hematol Oncol 2003;20:173-185.